Business Description
Capricor Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US14070B1017
Description
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.56 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 18.04 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 260.9 | |||||
| 3-Year EBITDA Growth Rate | 0.4 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | -14.9 | |||||
| 3-Year Book Growth Rate | -19.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 69.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.83 | |||||
| 9-Day RSI | 53.3 | |||||
| 14-Day RSI | 53.76 | |||||
| 6-1 Month Momentum % | 263.61 | |||||
| 12-1 Month Momentum % | 628.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.19 | |||||
| Quick Ratio | 4.19 | |||||
| Cash Ratio | 4.15 | |||||
| Days Sales Outstanding | 37.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.8 | |||||
| Shareholder Yield % | -10.87 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -155.62 | |||||
| Net Margin % | -146.86 | |||||
| FCF Margin % | -164.99 | |||||
| ROE % | -143.31 | |||||
| ROA % | -61.67 | |||||
| ROIC % | -129.38 | |||||
| ROC (Joel Greenblatt) % | -491.07 | |||||
| ROCE % | -126.26 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 25.49 | |||||
| PB Ratio | 11.27 | |||||
| Price-to-Tangible-Book | 11.27 | |||||
| EV-to-EBIT | -21.67 | |||||
| EV-to-Forward-EBIT | -16.18 | |||||
| EV-to-EBITDA | -22.51 | |||||
| EV-to-Forward-EBITDA | -16.18 | |||||
| EV-to-Revenue | 33.72 | |||||
| EV-to-Forward-Revenue | 65.27 | |||||
| EV-to-FCF | -20.44 | |||||
| Price-to-Median-PS-Value | 1.69 | |||||
| Price-to-Net-Current-Asset-Value | 12.53 | |||||
| Price-to-Net-Cash | 12.69 | |||||
| Earnings Yield (Greenblatt) % | -4.61 | |||||
| FCF Yield % | -4.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CAPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Capricor Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 23.228 | ||
| EPS (TTM) ($) | -1.02 | ||
| Beta | 1.08 | ||
| Volatility % | 243.93 | ||
| 14-Day RSI | 53.76 | ||
| 14-Day ATR ($) | 1.722222 | ||
| 20-Day SMA ($) | 18.70575 | ||
| 12-1 Month Momentum % | 628.43 | ||
| 52-Week Range ($) | 2.9 - 23.4 | ||
| Shares Outstanding (Mil) | 45.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Capricor Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Capricor Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Capricor Therapeutics Inc Frequently Asked Questions
What is Capricor Therapeutics Inc(CAPR)'s stock price today?
The current price of CAPR is $19.04. The 52 week high of CAPR is $23.40 and 52 week low is $2.90.
When is next earnings date of Capricor Therapeutics Inc(CAPR)?
The next earnings date of Capricor Therapeutics Inc(CAPR) is 2025-02-28 Est..
Does Capricor Therapeutics Inc(CAPR) pay dividends? If so, how much?
Capricor Therapeutics Inc(CAPR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers